Bipolar DisorderPhase 4NCT00067938
Bipolar Study in Adults at Least 18 Years of Age
A Phase 4 study testing lamotrigine in people with Bipolar Disorder, run by GlaxoSmithKline at 308 sites in United States.
Trial summary
Bipolar study of tolerability, clinical response and patient satisfaction Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Bipolar Disorder
- What is being tested?
- lamotrigine
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 1,200 participants
- Where
- 308 sitesUnited States
- Study dates
- Aug 2003to Aug 2004
- Phase
- Phase 4
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Diagnosis of bipolar I disorder.
- Must be on a stable regimen of psychiatric medication for at least 2 months prior to study.
- If female, must not be pregnant, or must be incapable of conceiving or be taking steps to prevent conception.
Who cannot join
- Patients with a clinically significant psychiatric or physiologic comorbidity including significant substance abuse, depression or mania which is of an unstable of progressive nature that could interfere in participation of this study.
- Presence of untreated thyroid disease.
- Patient is actively suicidal or homicidal.
- Patient has history of severe hepatic or renal insufficiency.
- Patient is currently participating in another clinical trial.
Trial locations and contacts
308 sites in 1 country.
300 sites in 1 country
United States300 sites
GSK Investigational Site
Adrian, Michigan, 49221
GSK Investigational Site
Albany, New York, 31701
GSK Investigational Site
Albertville, Alabama, 35950
GSK Investigational Site
Albuquerque, New Mexico, 87108
GSK Investigational Site
Altamonte Springs, Florida, 32714
GSK Investigational Site
Alton, Illinois, 62002
GSK Investigational Site
Amityville, New York, 11701
GSK Investigational Site
Annapolis, Maryland, 21403
GSK Investigational Site
Anniston, Alabama, 36207
GSK Investigational Site
Arlington, Texas, 76012
GSK Investigational Site
Arlington, Virginia, 22205
GSK Investigational Site
Ashburn, Virginia, 20147
GSK Investigational Site
Atlanta, Georgia, 30030
GSK Investigational Site
Atlanta, Georgia, 30309-7520
GSK Investigational Site
Atlanta, Georgia, 30338
GSK Investigational Site
Austin, Texas, 78759
GSK Investigational Site
Avon Lake, Ohio, 44012
GSK Investigational Site
Bakersfield, California, 93309
GSK Investigational Site
Baltimore, Maryland, 21239
GSK Investigational Site
Batlimore, Maryland, 21208
GSK Investigational Site
Baton Rouge, Louisiana, 70806
GSK Investigational Site
Bay City, Michigan, 48706
GSK Investigational Site
Bedford, Texas, 76022
GSK Investigational Site
Bellingham, Washington, 98225
GSK Investigational Site
Benton Harbor, Michigan, 49022
GSK Investigational Site
Beverly Hills, California, 90210
GSK Investigational Site
Billings, Montana, 59101
GSK Investigational Site
Birmingham, Alabama, 35209
GSK Investigational Site
Birmingham, Alabama, 35223
GSK Investigational Site
Birmingham, Alabama, 35234
GSK Investigational Site
Bloomfield Hills, Michigan, 48302
GSK Investigational Site
Boca Raton, Florida, 33432
GSK Investigational Site
Boca Raton, Florida, 33433
GSK Investigational Site
Boise, Idaho, 83702
GSK Investigational Site
Boise, Idaho, 83704
GSK Investigational Site
Boise, Idaho, 83706
GSK Investigational Site
Boulder, Colorado, 80303
GSK Investigational Site
Bourbonnais, Illinois, 60914
GSK Investigational Site
Boynton Beach, Florida, 33426
GSK Investigational Site
Bradenton, Florida, 34209
GSK Investigational Site
Brandon, Florida, 33511
GSK Investigational Site
Bristol, Tennessee, 37620
GSK Investigational Site
Brownstown Township, Michigan, 48183
GSK Investigational Site
Burbank, California, 91501
GSK Investigational Site
Burtonsville, Maryland, 20866
GSK Investigational Site
Campbell, California, 95008
GSK Investigational Site
Cary, North Carolina, 27511
GSK Investigational Site
Casselberry, Florida, 32730
GSK Investigational Site
Cedar Rapids, Iowa, 52402
GSK Investigational Site
Cerritos, California, 90703
GSK Investigational Site
Chandler, Arizona, 85225
GSK Investigational Site
Chapel Hill, North Carolina, 27514
GSK Investigational Site
Chapel Hill, North Carolina, 27517
GSK Investigational Site
Charleston, South Carolina, 29407
GSK Investigational Site
Charleston, West Virginia, 25301
GSK Investigational Site
Charleston, West Virginia, 25309
GSK Investigational Site
Charlotte, North Carolina, 28211
GSK Investigational Site
Charlottesville, Virginia, 22903
GSK Investigational Site
Charlottesville, Virginia, 22911
GSK Investigational Site
Chicago, Illinois, 60657
GSK Investigational Site
Christiansburg, Virginia, 24073
GSK Investigational Site
Cincinnati, Ohio, 45206
GSK Investigational Site
Cincinnati, Ohio, 45243
GSK Investigational Site
Clearwater, Florida, 33764
GSK Investigational Site
Clinton Township, Michigan, 48036
GSK Investigational Site
Colmar, Pennsylvania, 18915
GSK Investigational Site
Conroe, Texas, 77304
GSK Investigational Site
Coral Springs, Florida, 33065
GSK Investigational Site
Cordova, Tennessee, 38016
GSK Investigational Site
Cornelius, North Carolina, 28031
GSK Investigational Site
Cuyahoga Falls, Ohio, 44221
GSK Investigational Site
Dallas, Texas, 75219
GSK Investigational Site
Danville, Indiana, 46122
GSK Investigational Site
Danville, Virginia, 24541
GSK Investigational Site
Davie, Florida, 33024
GSK Investigational Site
Dayton, Ohio, 45459
GSK Investigational Site
Daytona Beach, Florida, 32114
GSK Investigational Site
Decatur, Georgia, 30030
GSK Investigational Site
Destin, Florida, 32541
GSK Investigational Site
Doyletown, Pennsylvania, 18901
GSK Investigational Site
Dubuque, Iowa, 52001
GSK Investigational Site
Duluth, Minnesota, 55802
GSK Investigational Site
Durham, North Carolina, 27705
GSK Investigational Site
East Lansing, Michigan, 48823
GSK Investigational Site
East Moline, Illinois, 61244
GSK Investigational Site
El Centro, California, 92243
GSK Investigational Site
Ellicott City, Maryland, 21043
GSK Investigational Site
Evansville, Indiana, 47715
GSK Investigational Site
Everett, Washington, 98201
GSK Investigational Site
Evergreen Park, Illinois, 60805
GSK Investigational Site
Fairfield, California, 94533
GSK Investigational Site
Fairhope, Alabama, 36532
GSK Investigational Site
Fairview Heights, Illinois, 62208
GSK Investigational Site
Falls Church, Virginia, 22041
GSK Investigational Site
Farmingdale, New York, 11735
GSK Investigational Site
Farmington Hills, Michigan, 48334
GSK Investigational Site
Fayetteville, North Carolina, 28305
GSK Investigational Site
Flint, Michigan, 48507
GSK Investigational Site
Flint, Michigan, 48532
GSK Investigational Site
Flowood, Mississippi, 39232
GSK Investigational Site
Forest City, North Carolina, 28043
GSK Investigational Site
Fort Collins, Colorado, 80525
GSK Investigational Site
Fort Smith, Arkansas, 72903
GSK Investigational Site
Fort Walton Beach, Florida, 32548
GSK Investigational Site
Fort Wayne, Indiana, 46805
GSK Investigational Site
Gainesville, Florida, 32607
GSK Investigational Site
Gaithersburg, Maryland, 20877
GSK Investigational Site
Glen Burnie, Maryland, 21061
GSK Investigational Site
Goldsboro, North Carolina, 27530
GSK Investigational Site
Granite City, Illinois, 62040
GSK Investigational Site
Greensboro, North Carolina, 27408
GSK Investigational Site
Greenville, North Carolina, 27834
GSK Investigational Site
Greenville, North Carolina, 27858
GSK Investigational Site
Gulfport, Mississippi, 39503
GSK Investigational Site
Hamden, Connecticut, 06514
GSK Investigational Site
Henderson, Nevada, 89074
GSK Investigational Site
High Point, North Carolina, 27262
GSK Investigational Site
Hopkinsville, Kentucky, 42240
GSK Investigational Site
Houma, Louisiana, 70360
GSK Investigational Site
Houston, Texas, 77007
GSK Investigational Site
Houston, Texas, 77014
GSK Investigational Site
Houston, Texas, 77027
GSK Investigational Site
Houston, Texas, 77030
GSK Investigational Site
Houston, Texas, 77042
GSK Investigational Site
Houston, Texas, 77057
GSK Investigational Site
Houston, Texas, 77074
GSK Investigational Site
Humble, Texas, 77338
GSK Investigational Site
Humble, Texas, 77339
GSK Investigational Site
Huntsville, Alabama, 35802
GSK Investigational Site
Irving, Texas, 75062
GSK Investigational Site
Jacksonville, Florida, 32216
GSK Investigational Site
Jacksonville, Florida, 32257
GSK Investigational Site
Jacksonville Beach, Florida, 32250
GSK Investigational Site
Johnson City, Tennessee, 37601
GSK Investigational Site
Joliet, Illinois, 60435
GSK Investigational Site
Joplin, Missouri, 64804
GSK Investigational Site
Kansas City, Missouri, 64108
GSK Investigational Site
Kingsport, Tennessee, 37664
GSK Investigational Site
Kingston, Pennsylvania, 18704
GSK Investigational Site
Kingwood, Texas, 77339
GSK Investigational Site
Knoxville, Tennessee, 37919
GSK Investigational Site
Knoxville, Tennessee, 37922
GSK Investigational Site
La Mesa, California, 91941
GSK Investigational Site
Lafayette, Indiana, 47904
GSK Investigational Site
Laguna Hills, California, 92653
GSK Investigational Site
Lake Charles, Louisiana, 70601
GSK Investigational Site
Lakeland, Florida, 33803
GSK Investigational Site
Las Cruces, New Mexico, 88011
GSK Investigational Site
Las Vegas, Nevada, 89030
GSK Investigational Site
Las Vegas, Nevada, 89102
GSK Investigational Site
Latham, New York, 12110
GSK Investigational Site
Laurel, Maryland, 20707
GSK Investigational Site
Lawrenceville, Georgia, 30045
GSK Investigational Site
Leavenworth, Kansas, 66048
GSK Investigational Site
Lexington, Kentucky, 40509
GSK Investigational Site
Libertyville, Illinois, 60048
GSK Investigational Site
Lincoln, Nebraska, 68502
GSK Investigational Site
Lisle, Illinois, 60532
GSK Investigational Site
Little Rock, Arkansas, 72201
GSK Investigational Site
Long Branch, New Jersey, 07740
GSK Investigational Site
Los Angeles, California, 90011
GSK Investigational Site
Los Angeles, California, 90089
GSK Investigational Site
Macon, Georgia, 31201
GSK Investigational Site
Madison, Tennessee, 37115
GSK Investigational Site
Manchester, New Hampshire, 03104
GSK Investigational Site
Mansfield Center, Connecticut, 06250
GSK Investigational Site
McKeesport, Pennsylvania, 15132
GSK Investigational Site
Media, Pennsylvania, 19063
GSK Investigational Site
Mequion, Wisconsin, 53092
GSK Investigational Site
Miami, Florida, 32216
GSK Investigational Site
Miami, Florida, 33125
GSK Investigational Site
Miami, Florida, 33157
GSK Investigational Site
Miami, Florida, 33176
GSK Investigational Site
Midlothian, Virginia, 23112
GSK Investigational Site
Milwaukee, Wisconsin, 53226
GSK Investigational Site
Milwaukie, Oregon, 97222
GSK Investigational Site
Minneapolis, Minnesota, 55454
GSK Investigational Site
Mishawaka, Indiana, 46545
GSK Investigational Site
Moncks Corner, South Carolina, 29461
GSK Investigational Site
Mount Clemens, Michigan, 48043
GSK Investigational Site
Murfreesboro, Tennessee, 37129
GSK Investigational Site
Nacogdoches, Texas, 75965
GSK Investigational Site
Nashville, Tennessee, 37203
GSK Investigational Site
Nashville, Tennessee, 37204
GSK Investigational Site
Natrona Heights, Pennsylvania, 15065
GSK Investigational Site
New Rochelle, New York, 10801
GSK Investigational Site
New York, New York, 10023
GSK Investigational Site
Newark, Delaware, 19713
GSK Investigational Site
Newport News, Virginia, 23606
GSK Investigational Site
Norfolk, Virginia, 23505
GSK Investigational Site
North Charleston, South Carolina, 29406
GSK Investigational Site
North Little Rock, Arkansas, 72113
GSK Investigational Site
North Miami, Florida, 33161
GSK Investigational Site
Norwich, Connecticut, 06360
GSK Investigational Site
Oakbrook Terrace, Illinois, 60181
GSK Investigational Site
Oakdale, Minnesota, 55128
GSK Investigational Site
Ocala, Florida, 34471
GSK Investigational Site
Ocala, Florida, 34474
GSK Investigational Site
Oceanside, California, 92056
GSK Investigational Site
Oklahoma City, Oklahoma, 73103
GSK Investigational Site
Oklahoma City, Oklahoma, 73109
GSK Investigational Site
Oklahoma City, Oklahoma, 73118
GSK Investigational Site
Oklahoma City, Oklahoma, 73120
GSK Investigational Site
Olean, New York, 14760
GSK Investigational Site
Omaha, Nebraska, 68124
GSK Investigational Site
Omaha, Nebraska, 68131
GSK Investigational Site
Orange City, Florida, 32763
GSK Investigational Site
Orland Park, Illinois, 60462
GSK Investigational Site
Orlando, Florida, 32803
GSK Investigational Site
Overland Park, Kansas, 66211
GSK Investigational Site
Palm Beach Gardens, Florida, 33410
GSK Investigational Site
Park Ridge, Illinois, 60068
GSK Investigational Site
Pensacola, Florida, 32503
GSK Investigational Site
Petaluma, California, 94952
GSK Investigational Site
Philadelphia, Pennsylvania, 19139
GSK Investigational Site
Phoenix, Arizona, 85004
GSK Investigational Site
Phoenix, Arizona, 85018
GSK Investigational Site
Phoenix, Arizona, 85032
GSK Investigational Site
Phoenix, Arizona, 85044
GSK Investigational Site
Pittsburgh, Pennsylvania, 15243
GSK Investigational Site
Plantation, Florida, 33324
GSK Investigational Site
Plymouth, Indiana, 46563
GSK Investigational Site
Port Jefferson, New York, 11777
GSK Investigational Site
Portland, Oregon, 97210
GSK Investigational Site
Portsmouth, Virginia, 23703
GSK Investigational Site
Poway, California, 92064
GSK Investigational Site
Princeton, New Jersey, 08540
GSK Investigational Site
Racine, Wisconsin, 53403
GSK Investigational Site
Raleigh, North Carolina, 27605
GSK Investigational Site
Raleigh, North Carolina, 27607
GSK Investigational Site
Raleigh, North Carolina, 27609
GSK Investigational Site
Raleigh, North Carolina, 27612
GSK Investigational Site
Reading, Pennsylvania, 19610
GSK Investigational Site
Renton, Washington, 98055
GSK Investigational Site
Richmond, Virginia, 23230
GSK Investigational Site
Riverside, California, 92506
GSK Investigational Site
Rochester Hills, Michigan, 48307
GSK Investigational Site
Rockford, Illinois, 61108
GSK Investigational Site
Rockville, Maryland, 20852
GSK Investigational Site
Rogers, Arizona, 72756
GSK Investigational Site
Roswell, Georgia, 30075
GSK Investigational Site
Royal Oak, Michigan, 48067
GSK Investigational Site
Sacramento, California, 95825
GSK Investigational Site
Saint Charles, Missouri, 63301
GSK Investigational Site
Salt Lake City, Utah, 84102
GSK Investigational Site
San Antonio, Texas, 78229
GSK Investigational Site
San Antonio, Texas, 78232
GSK Investigational Site
San Diego, California, 92103
GSK Investigational Site
San Diego, California, 92114
GSK Investigational Site
San Diego, California, 92123
GSK Investigational Site
San Jose, California, 95123
GSK Investigational Site
Santa Ana, California, 92705
GSK Investigational Site
Santa Barbara, California, 93102
GSK Investigational Site
Sarasota, Florida, 34238
GSK Investigational Site
Schaumburg, Illinois, 60194
GSK Investigational Site
Shawnee Mission, Kansas, 66214
GSK Investigational Site
Sherman Oaks, California, 91403
GSK Investigational Site
Shreveport, Louisiana, 71101
GSK Investigational Site
Smithtown, New York, 11787
GSK Investigational Site
Spokane, Washington, 99204
GSK Investigational Site
Springfield, Missouri, 65804
GSK Investigational Site
St Louis, Missouri, 63117
GSK Investigational Site
St Louis, Missouri, 63128
GSK Investigational Site
St Louis, Missouri, 63136-3675
GSK Investigational Site
St. Petersburg, Florida, 33701
GSK Investigational Site
St. Petersburg, Florida, 33702
GSK Investigational Site
Stockbridge, Georgia, 30281
GSK Investigational Site
Suffolk, Virginia, 23434
GSK Investigational Site
Sugar Land, Texas, 77478
GSK Investigational Site
Syracuse, Florida, 13202
GSK Investigational Site
Tacoma, Washington, 98499
GSK Investigational Site
Tampa, Florida, 33603
GSK Investigational Site
The Bronx, New York, 10461
GSK Investigational Site
Topeka, Kansas, 66606
GSK Investigational Site
Torrance, California, 90505
GSK Investigational Site
Towson, Maryland, 21204
GSK Investigational Site
Towson, Maryland, 21286
GSK Investigational Site
Tucson, Arizona, 85719
GSK Investigational Site
Tulsa, Oklahoma, 74120
GSK Investigational Site
Tulsa, Oklahoma, 74136
GSK Investigational Site
Tuscaloosa, Alabama, 35404
GSK Investigational Site
Tyler, Texas, 75702
GSK Investigational Site
Valparaiso, Indiana, 46383
GSK Investigational Site
Vernon Hills, Illinois, 60061
GSK Investigational Site
Virginia Beach, Virginia, 23452
GSK Investigational Site
Warner Robins, Georgia, 31093
GSK Investigational Site
Warren, Ohio, 44483
GSK Investigational Site
Washington D.C., District of Columbia, 20011
GSK Investigational Site
Waukesha, Wisconsin, 53188
GSK Investigational Site
Wauwatosa, Wisconsin, 53213
GSK Investigational Site
Weirton, West Virginia, 26062
GSK Investigational Site
West Allis, Wisconsin, 53227
GSK Investigational Site
West Hollywood, California, 90048
GSK Investigational Site
West Palm Beach, Florida, 33407
GSK Investigational Site
Wethersfield, Connecticut, 06109
GSK Investigational Site
Wheaton, Illinois, 60187
GSK Investigational Site
Wichita, Kansas, 67205
GSK Investigational Site
Wichita, Kansas, 67206
GSK Investigational Site
Wichita, Kansas, 67207
GSK Investigational Site
Wichita, Kansas, 67211
About this study
Official title: Lamictal for Use in Treatment of Bipolar Disorder In Adults. A Practical Clinical Assessment of Tolerability and Clinical Effectiveness.
Bipolar study of tolerability, clinical response and patient satisfaction
- Conditions
- Bipolar Disorder
- Being tested
- lamotrigine
- Keywords
- bipolar disorder, lamotrigine
- Medical subject headings
- Bipolar Disorder
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
lamotrigineDrug
Lamotrigine
| Study group | Role | What they receive |
|---|---|---|
| Arm 1 | Other | Open label single arm study Receives: Drug: lamotrigine |
What is being measured
The primary outcome is the main question the study is designed to answer.
The primary endpoint will be the rate of rash during 12 weeks.
Measured: 12 Weeks
Secondary outcomes (1)
Change from baseline in Week 5 and Week 12 Clinical Global Impression-Bipolar version (CGI-BP) Severityand Improvement scores.
Measured: 12 Weeks
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted5 Sep 2003 (estimated)
- Study startAug 2003
- Primary completionAug 2004
- Study completionAug 2004
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Bipolar DisorderStudies of the same condition, open and under way.
- More trials run by GlaxoSmithKlineThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 4
- Primary purpose
- Treatment
- Allocation
- Non-randomised
- Intervention model
- Single group
- Masking
- None (open label)
- Enrolment
- 1,200 participants (actual)
Sponsor and investigators
- Lead sponsor
- GlaxoSmithKline
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
- Investigators
- GSK Clinical Trials, Study director, GlaxoSmithKline
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT00067938
- Sponsor's protocol ID
- SCA40917
- Status last verified
- Aug 2016
- First submitted
- 3 Sep 2003
- Last updated
- 1 Sep 2016
- Results posted
- No
- Data monitoring committee
- No
- Individual data sharing
- Yes: Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.
Study at a glance
From the registry record, last updated by the sponsor on 1 Sep 2016. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Lamictal for Use in Treatment of Bipolar Disorder In Adults. A Practical Clinical Assessment of Tolerability and Clinical Effectiveness.
- ClinicalTrials.gov ID
- NCT00067938
- Acronym / sponsor ID
- SCA40917
- Conditions
- Bipolar Disorder
- Keywords
- bipolar disorder, lamotrigine
- Phase
- Phase 4
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 1,200 participants (actual)
- Lead sponsor
- GlaxoSmithKlineIndustry (pharma, biotech, devices)
- Study start
- Aug 2003
- Primary completion
- Aug 2004 (actual)
- Study completion
- Aug 2004 (actual)
- First posted
- 5 Sep 2003 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Bipolar study of tolerability, clinical response and patient satisfaction
Study design
- Primary purpose
- Treatment
- Allocation
- Non-randomised
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Arm 1 | Other | Drug: lamotrigineOpen label single arm study |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (3 listed)
- Diagnosis of bipolar I disorder.
- Must be on a stable regimen of psychiatric medication for at least 2 months prior to study.
- If female, must not be pregnant, or must be incapable of conceiving or be taking steps to prevent conception.
Key exclusion criteria (5 listed)
- Patients with a clinically significant psychiatric or physiologic comorbidity including significant substance abuse, depression or mania which is of an unstable of progressive nature that could interfere in participation of this study.
- Presence of untreated thyroid disease.
- Patient is actively suicidal or homicidal.
- Patient has history of severe hepatic or renal insufficiency.
- Patient is currently participating in another clinical trial.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| lamotrigineLamotrigine | Drug | Arm 1 |
Primary outcome
The primary endpoint will be the rate of rash during 12 weeks.
Time frame: 12 Weeks
1 secondary outcome
Change from baseline in Week 5 and Week 12 Clinical Global Impression-Bipolar version (CGI-BP) Severityand Improvement scores.
Time frame: 12 Weeks
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 1 Sep 2016.
- Researchers can use this site to request access to anonymised patient level data and/or supporting documents from clinical studies to conduct further research.Link provided by the sponsor.
- Individual participant dataSharing planned: Yes. Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.
Related trials for Bipolar Disorder
Not yet recruitingObservational study
Sleep Monitoring for Early Detection of Relapse in People With Schizophrenia or Bipolar Disorder Receiving Usual Treatment
Bipolar Disorder (BD), SCHIZOPHRENIA 1 (Disorder)
Recruiting
Safety and Feasibility of DBS for Bipolar Depression
Bipolar I Disorder, Bipolar Depression
Not yet recruiting
Compulsive Eating and Brain's Reward System in Different Pathologies
PARKINSON DISEASE (Disorder), Bipolar 1 Disorder
Not yet recruitingPhase 1
Pharmacokinetics and Relative Bioavailability of Intranasal vs Intramuscular Olanzapine in Healthy Adult Participants
Healthy Adult Participants
Recruiting
Affective Cognitive Training in Mood Disorders and High-risk Relatives
Major Depressive Disorder (MDD), Bipolar Disorder (BD)
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
GSK Clinical Trials study director
GlaxoSmithKline
308 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 4 study testing lamotrigine in people with Bipolar Disorder, run by GlaxoSmithKline at 308 sites in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 5 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 1 Sep 2016. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 308 sites in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 4 studies take place after a treatment is approved, to learn more about its long-term benefits and risks in everyday use.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
The primary endpoint will be the rate of rash during 12 weeks. (time frame: 12 Weeks). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 1 Sep 2016.